Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05508737 | Dec 2022 → Nov 2025 overdue | gastroesophageal adenocarcinoma | Yonsei University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05508737 ↗ |
| Known as | Trifluridine/Tipiracil (Lonsurf) | “Trifluridine/Tipiracil (Lonsurf®)” NCT05508737 ↗ |